---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037257"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2026-08-12T12:45:32+00:00"
generated_at: "2026-08-12T12:50:05.501188+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q2 2026 revenue flat at $961K; net loss $2.12M, cash down to $4.79M

## Summary
- Revenue $961,138, down 0.6% YoY; grant revenue up $334K, R&D revenue down $89.6K.
- Net loss $2,123,884 ($0.06/share) vs $1,793,774 ($0.06/share) a year ago.
- Cash and investments $4.79M at June 30, down from $8.59M at Dec 31, 2025.
- Commercial progress: shipments of 6 recombinant proteins, pilot sales for cultivated meat, IBT Bioservices OEM shipments, Proliant Albufree DX launch.
- Transferrin productivity up ~80% at pilot scale; Gates Foundation RSV/malaria mAb programs advancing.

## SEC filing metadata
- accession: 0001493152-26-037257
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2026-08-12T12:45:32+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/0001493152-26-037257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037257
- JSON: https://secwatch.observer/filing/0001493152-26-037257.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.